CM
PCRX icon

Castleark Management’s Pacira BioSciences PCRX Stock Holding History

Castleark Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-49,580
Closed -$2.89M – 321
2022
Q2 		$2.89M Sell
49,580
-11,080
-18% -$726K 0.15% 137
2022
Q1 		$4.63M Buy
+60,660
New +$4.04M 0.2% 117
2019
Q1 		– Sell
-119,440
Closed -$5.14M – 394
2018
Q4 		$5.14M Sell
119,440
-106,105
-47% -$4.95M 0.22% 143
2018
Q3 		$11.1M Buy
+225,545
New +$9.75M 0.32% 107
2016
Q1 		– Sell
-144,060
Closed -$11.1M – 403
2015
Q4 		$11.1M Buy
+144,060
New +$8.16M 0.33% 77
2015
Q1 		– Sell
-129,325
Closed -$11.5M – 373
2014
Q4 		$11.5M Buy
129,325
+41,986
+48% +$3.97M 0.3% 96
2014
Q3 		$6.11M Sell
87,339
-4,000
-4% -$389K 0.17% 137
2014
Q2 		$8.39M Buy
91,339
+4,000
+5% +$305K 0.23% 98
2014
Q1 		$6.11M Sell
87,339
-39,399
-31% -$2.68M 0.17% 137
2013
Q4 		$7.29M Buy
126,738
+45,902
+57% +$2.41M 0.21% 88
2013
Q3 		$7.83M Sell
80,836
-47,999
-37% -$1.75M 0.22% 117
2013
Q2 		$3.74M Buy
+128,835
New +$3.73M 0.12% 131

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.85B AUM 15.7% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Castleark Management's PCRX Position: Q3 2022 in Review

Castleark Management sold out of Pacira BioSciences (PCRX) in Q3 2022, closing a stake of 49,580 shares — an estimated $2.89M sold.

Castleark Management first reported a position in PCRX in Q2 2013 and held it in 12 quarters. The position peaked at $11.5M in Q4 2014. 272 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.

  • Castleark Management reported no remaining Pacira BioSciences position as of Q3 2022 after selling out during the quarter.
  • Castleark Management sold 49,580 Pacira BioSciences shares in Q3 2022, an estimated $2.89M.
  • Castleark Management first reported a position in Pacira BioSciences in Q2 2013 and held it in 12 quarters.
  • Castleark Management's Pacira BioSciences position peaked at $11.5M in Q4 2014.
  • 272 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.

Based on Castleark Management's 13F filing for Q3 2022, filed 15 Nov 2022.